2 active not recruiting, 2 recruiting, 1 not yet recruiting. 4 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 2, Active not recruiting 1, Not yet recruiting 1 |
| Phase 1 | 3 | Recruiting 2, Active not recruiting 1 |
Follow Unresectable Merkel Cell Carcinoma: new trials by email Literature Review of Unresectable Merkel Cell Carcinoma trials Research Report on Unresectable Merkel Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 50 | 2026-12-01 | 2026-09-17 |
| Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 16 | 2024-07-24 | 2026-10-14 |
| Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial Avelumab, Biopsy Procedure, Biospecimen Collection - Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 50 | 2024-05-21 | 2026-07-31 |
| Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 138 | 2022-03-31 | 2026-08-20 |
| Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers Ipilimumab, Nivolumab, Prednisone - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 12 | 2019-11-08 | 2026-10-14 |
Carcinoma, Merkel Cell (5) · Melanoma (4) · Carcinoma, Basal Cell (3) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Renal Cell (2) · Carcinoma, Transitional Cell (2) · Lung Neoplasms (2) · Neoplasm Metastasis (2) · Squamous Cell Carcinoma of Head and Neck (2) · Uterine Cervical Neoplasms (2) · Carcinoma, Hepatocellular (1) · Carcinoma, Lobular (1) · Carcinosarcoma (1) · Clear-cell metastatic renal cell carcinoma (1) · Colorectal Neoplasms (1)
Adenocarcinoma (5) · Carcinoma (5) · Carcinoma, Neuroendocrine (5) · DNA Virus Infections (5) · Infections (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Neoplasms, Germ Cell and Embryonal (5) · Neoplasms, Glandular and Epithelial (5) · Neoplasms, Nerve Tissue (5) · Neuroectodermal Tumors (5) · Neuroendocrine Tumors (5) · Polyomavirus Infections (5) · Tumor Virus Infections (5) · Virus Diseases (5)
Magnetic Resonance Spectroscopy (4) · Specimen Handling (4) · Biopsy (3) · Nivolumab (3) · CTLA-4 Antigen (2) · Ipilimumab (2) · Prednisone (2) · deltacortene (2) · prednylidene (2) · Colony-Stimulating Factors (1) · Cyclophosphamide (1) · Immunoglobulin G (1) · Sirolimus (1) · Tacrolimus (1) · X-Rays (1)
National Cancer Institute (NCI) (3) · Fred Hutchinson Cancer Center (1) · Mayo Clinic (1)
United States (4) · Canada (1) · Uganda (1)
Evan J Lipson (2) · Paul Nghiem (1) · Shailender Bhatia, MD (1) · Yanyan Lou, MD, PhD (1)
PMID 32503950, PMID 36821617, PMID 38252910
UM1CA186691 (2), P30CA015704 (1)